US 12,139,529 B2
Antibody-peptide fusion proteins for treating amyloid disorders
Jonathan S. Wall, Knoxville, TN (US); James S. Foster, Knoxville, TN (US); Spencer Guthrie, San Francisco, CA (US); Jaume Pons, San Francisco, CA (US); and Michael L. Klein, San Francisco, CA (US)
Assigned to UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION, Knoxville, TN (US); and ATTRALUS, INC., Burlingame, CA (US)
Filed by UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION, Knoxville, TN (US); and Attralus, Inc., San Francisco, CA (US)
Filed on Apr. 11, 2023, as Appl. No. 18/298,953.
Application 18/298,953 is a continuation of application No. PCT/US2022/072413, filed on May 18, 2022.
Claims priority of provisional application 63/190,191, filed on May 18, 2021.
Prior Publication US 2023/0416347 A1, Dec. 28, 2023
Int. Cl. C07K 16/18 (2006.01); A61K 51/10 (2006.01); C07K 14/00 (2006.01)
CPC C07K 16/18 (2013.01) [A61K 51/1093 (2013.01); C07K 14/001 (2013.01); C07K 2317/77 (2013.01); C07K 2317/92 (2013.01); C07K 2319/30 (2013.01)] 9 Claims
 
1. An antibody-peptide fusion protein, comprising:
an antibody that binds to human amyloid fibrils comprising i) a heavy chain and ii) a light chain with an amyloid-reactive peptide fused to the C-terminus of the light chain via a linker,
wherein the heavy chain comprises the amino acid sequence of SEQ ID NO:91, and the light chain with the amyloid-reactive peptide fused to the C-terminus of the light chain via the linker comprises the amino acid sequence of SEQ ID NO:89.